Skip to content
10-K

Annual Report

OS THERAPIES INCORPORATED OSTX

0001213900-26-036629

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 39.53M sh
Shares Diluted FY 2025 · Dec 31, 2025 29.25M sh
Shares Diluted FY 2025 · Dec 31, 2024 6.95M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$14.24M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$7.28M
Cash And Equivalents FY 2025 · Dec 31, 2025 $269.83K
Cash And Equivalents FY 2025 · Dec 31, 2024 $5.53M
Cash And Equivalents FY 2025 · Dec 31, 2023 $38.98K
Stockholders Equity FY 2025 · Dec 31, 2025 −$6.1M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$3.27M
Stockholders Equity FY 2025 · Dec 31, 2023 −$24.02M
Current Liabilities FY 2025 · Dec 31, 2025 $11.76M
Current Liabilities FY 2025 · Dec 31, 2024 $4.63M
Total Liabilities FY 2025 · Dec 31, 2025 $11.86M
Total Liabilities FY 2025 · Dec 31, 2024 $4.73M
Current Assets FY 2025 · Dec 31, 2025 $332.91K
Current Assets FY 2025 · Dec 31, 2024 $5.53M
Total Assets FY 2025 · Dec 31, 2025 $6.84M
Total Assets FY 2025 · Dec 31, 2024 $5.54M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.98
Eps Diluted restated FY 2025 · Dec 31, 2024 −$1.28
Eps Basic FY 2025 · Dec 31, 2025 −$0.98
Eps Basic restated FY 2025 · Dec 31, 2024 −$1.28
Sga Expense FY 2025 · Dec 31, 2025 $12.34M
Sga Expense FY 2025 · Dec 31, 2024 $3.97M
Rd Expense FY 2025 · Dec 31, 2025 $16.36M
Rd Expense FY 2025 · Dec 31, 2024 $2.84M
Net Income FY 2025 · Dec 31, 2025 −$28.75M
Net Income FY 2025 · Dec 31, 2024 −$8.88M
Operating Income FY 2025 · Dec 31, 2025 −$28.71M
Operating Income FY 2025 · Dec 31, 2024 −$6.81M
Short Term Debt FY 2025 · Mar 7, 2024 $100K